Table 6. Effect of NSAID ever-use in each exposure period (in years before the index date) on the risk of developing total prostate cancer by NSAID category.
Variable | OR (95%CI)a | P-value |
Aspirin | ||
≤1 | 1.00 (0.87–1.16) | 0.954 |
1.1–6 | 0.93 (0.83–1.03) | 0.157 |
6.1–11 | 0.96 (0.87–1.06) | 0.409 |
11.1–16 | 1.02 (0.91–1.15) | 0.677 |
16.1–21 | 1.10 (0.96–1.27) | 0.161 |
21.1–26 | 1.00 (0.79–1.26) | 0.990 |
Arylacetic acids | ||
≤1 | 1.20 (1.06–1.37) | 0.005 |
1.1–6 | 0.99 (0.91–1.08) | 0.796 |
6.1–11 | 0.99 (0.90–1.09) | 0.813 |
11.1–16 | 0.94 (0.84–1.05) | 0.277 |
16.1–21 | 0.96 (0.83–1.12) | 0.642 |
21.1–26 | 0.77 (0.57–1.05) | 0.098 |
Butylpyrazolidines | ||
≤1 | 1.35 (0.45–4.05) | 0.589 |
1.1–6 | 1.25 (0.89–1.76) | 0.200 |
6.1–11 | 1.13 (0.91–1.41) | 0.262 |
11.1–16 | 0.79 (0.65–0.97) | 0.022 |
16.1–21 | 0.99 (0.80–1.23) | 0.931 |
21.1–26 | 1.05 (0.78–1.42) | 0.734 |
Oxicams | ||
≤1 | 0.90 (0.61–1.31) | 0.567 |
1.1–6 | 0.96 (0.81–1.15) | 0.683 |
6.1–11 | 1.01 (0.87–1.18) | 0.886 |
11.1–16 | 0.96 (0.81–1.14) | 0.674 |
16.1–21 | 0.84 (0.63–1.12) | 0.234 |
Propionates | ||
≤1 | 1.11 (0.96–1.30) | 0.164 |
1.1–6 | 0.93 (0.85–1.01) | 0.098 |
6.1–11 | 0.96 (0.88–1.05) | 0.426 |
11.1–16 | 0.85 (0.76–0.94) | 0.001 |
16.1–21 | 1.05 (0.92–1.20) | 0.439 |
21.1–26 | 0.87 (0.68–1.12) | 0.291 |
a) Adjusted for ever visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date, and to all terms listed in the table.